Eradication of hepatitis C virus infection in kidney transplant recipients using direct‐acting antiviral therapy: Qatar experience
<h3>Introduction</h3><p dir="ltr">Hepatitis C virus (HCV) infection has detrimental effects on patient and graft survival after kidney transplantation. In the pre-direct-acting antiviral (DAA) era, treatment of HCV infection was associated with low response rates, poor to...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | , , , , , , , , , , , , |
| Published: |
2020
|
| Subjects: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1864513565261561856 |
|---|---|
| author | Mohamad M. Alkadi (14778640) |
| author2 | Essa A. Abuhelaiqa (14778643) Mostafa F. Elshirbeny (14778646) Ahmed F. Hamdi (14778649) Omar M. Fituri (14778652) Muhammad Asim (2235472) Saad R. Alkaabi (14778655) Moutaz F. Derbala (14778658) Mona E. Jarman (14778661) Adel M. Ashour (14778664) Awais Nauman (14778667) Yousuf K. Al Maslamani (14778670) Adeel A. Butt (3697705) Hassan A. Al‐Malki (14778673) |
| author2_role | author author author author author author author author author author author author author |
| author_facet | Mohamad M. Alkadi (14778640) Essa A. Abuhelaiqa (14778643) Mostafa F. Elshirbeny (14778646) Ahmed F. Hamdi (14778649) Omar M. Fituri (14778652) Muhammad Asim (2235472) Saad R. Alkaabi (14778655) Moutaz F. Derbala (14778658) Mona E. Jarman (14778661) Adel M. Ashour (14778664) Awais Nauman (14778667) Yousuf K. Al Maslamani (14778670) Adeel A. Butt (3697705) Hassan A. Al‐Malki (14778673) |
| author_role | author |
| dc.creator.none.fl_str_mv | Mohamad M. Alkadi (14778640) Essa A. Abuhelaiqa (14778643) Mostafa F. Elshirbeny (14778646) Ahmed F. Hamdi (14778649) Omar M. Fituri (14778652) Muhammad Asim (2235472) Saad R. Alkaabi (14778655) Moutaz F. Derbala (14778658) Mona E. Jarman (14778661) Adel M. Ashour (14778664) Awais Nauman (14778667) Yousuf K. Al Maslamani (14778670) Adeel A. Butt (3697705) Hassan A. Al‐Malki (14778673) |
| dc.date.none.fl_str_mv | 2020-12-02T06:00:00Z |
| dc.identifier.none.fl_str_mv | 10.1002/iid3.386 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/Eradication_of_hepatitis_C_virus_infection_in_kidney_transplant_recipients_using_direct_acting_antiviral_therapy_Qatar_experience/22258183 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biomedical and clinical sciences Clinical sciences Immunology hepatitis C immunosuppression kidney function kidney transplantation |
| dc.title.none.fl_str_mv | Eradication of hepatitis C virus infection in kidney transplant recipients using direct‐acting antiviral therapy: Qatar experience |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <h3>Introduction</h3><p dir="ltr">Hepatitis C virus (HCV) infection has detrimental effects on patient and graft survival after kidney transplantation. In the pre-direct-acting antiviral (DAA) era, treatment of HCV infection was associated with low response rates, poor tolerance, and increased risk of allograft rejection. However, DAAs have revolutionized HCV treatment. The aims of this study were to determine the impact of DAA on the sustained virologic response (SVR), renal function, and calcineurin inhibitor (CNI) levels and assess the tolerability to treatment in kidney transplant recipients with HCV infection in Qatar.</p><h3>Methods</h3><p dir="ltr">This retrospective study included the medical records of all kidney transplant recipients with confirmed HCV infection before January 1, 2020. All data were obtained from the patients’ electronic medical records; these included patient demographics; virologic responses to treatment; serum creatinine levels during treatment; urine protein to creatinine ratios and CNI levels before, during, and after treatment; and side effects related to DAA therapy.</p><h3>Results</h3><p dir="ltr">A total of 27 kidney transplant recipients with HCV were identified, 23 of whom received DAA therapy. The length of treatment ranged from 12 to 24 weeks, and 52% of patients had HCV genotype 1 infection. The median log10 HCV RNA was 6.6 copies per milliliter. None of the patients had liver cirrhosis, and all of them achieved SVR. There was no statistically significant difference in the glomerular filtration rate before, during, and after treatment. Most patients had stable CNI trough levels during treatment and did not require dose adjustment.</p><h3>Conclusions</h3><p dir="ltr">HCV infection was successfully eradicated by DAA therapy in kidney transplant recipients, with a 100% SVR rate. Moreover, DAA therapy was well-tolerated, and kidney function remained stable without an increased risk of rejection. These results are expected to drive the eradication of hepatitis C from the entire country.</p><h2>Other Information</h2><p dir="ltr">Published in: Immunity, Inflammation and Disease<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="http://dx.doi.org/10.1002/iid3.386" target="_blank">http://dx.doi.org/10.1002/iid3.386</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_ef78a78c074f99d9191bbec5488ae361 |
| identifier_str_mv | 10.1002/iid3.386 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/22258183 |
| publishDate | 2020 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Eradication of hepatitis C virus infection in kidney transplant recipients using direct‐acting antiviral therapy: Qatar experienceMohamad M. Alkadi (14778640)Essa A. Abuhelaiqa (14778643)Mostafa F. Elshirbeny (14778646)Ahmed F. Hamdi (14778649)Omar M. Fituri (14778652)Muhammad Asim (2235472)Saad R. Alkaabi (14778655)Moutaz F. Derbala (14778658)Mona E. Jarman (14778661)Adel M. Ashour (14778664)Awais Nauman (14778667)Yousuf K. Al Maslamani (14778670)Adeel A. Butt (3697705)Hassan A. Al‐Malki (14778673)Biomedical and clinical sciencesClinical sciencesImmunologyhepatitis Cimmunosuppressionkidney functionkidney transplantation<h3>Introduction</h3><p dir="ltr">Hepatitis C virus (HCV) infection has detrimental effects on patient and graft survival after kidney transplantation. In the pre-direct-acting antiviral (DAA) era, treatment of HCV infection was associated with low response rates, poor tolerance, and increased risk of allograft rejection. However, DAAs have revolutionized HCV treatment. The aims of this study were to determine the impact of DAA on the sustained virologic response (SVR), renal function, and calcineurin inhibitor (CNI) levels and assess the tolerability to treatment in kidney transplant recipients with HCV infection in Qatar.</p><h3>Methods</h3><p dir="ltr">This retrospective study included the medical records of all kidney transplant recipients with confirmed HCV infection before January 1, 2020. All data were obtained from the patients’ electronic medical records; these included patient demographics; virologic responses to treatment; serum creatinine levels during treatment; urine protein to creatinine ratios and CNI levels before, during, and after treatment; and side effects related to DAA therapy.</p><h3>Results</h3><p dir="ltr">A total of 27 kidney transplant recipients with HCV were identified, 23 of whom received DAA therapy. The length of treatment ranged from 12 to 24 weeks, and 52% of patients had HCV genotype 1 infection. The median log10 HCV RNA was 6.6 copies per milliliter. None of the patients had liver cirrhosis, and all of them achieved SVR. There was no statistically significant difference in the glomerular filtration rate before, during, and after treatment. Most patients had stable CNI trough levels during treatment and did not require dose adjustment.</p><h3>Conclusions</h3><p dir="ltr">HCV infection was successfully eradicated by DAA therapy in kidney transplant recipients, with a 100% SVR rate. Moreover, DAA therapy was well-tolerated, and kidney function remained stable without an increased risk of rejection. These results are expected to drive the eradication of hepatitis C from the entire country.</p><h2>Other Information</h2><p dir="ltr">Published in: Immunity, Inflammation and Disease<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="http://dx.doi.org/10.1002/iid3.386" target="_blank">http://dx.doi.org/10.1002/iid3.386</a></p>2020-12-02T06:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1002/iid3.386https://figshare.com/articles/journal_contribution/Eradication_of_hepatitis_C_virus_infection_in_kidney_transplant_recipients_using_direct_acting_antiviral_therapy_Qatar_experience/22258183CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/222581832020-12-02T06:00:00Z |
| spellingShingle | Eradication of hepatitis C virus infection in kidney transplant recipients using direct‐acting antiviral therapy: Qatar experience Mohamad M. Alkadi (14778640) Biomedical and clinical sciences Clinical sciences Immunology hepatitis C immunosuppression kidney function kidney transplantation |
| status_str | publishedVersion |
| title | Eradication of hepatitis C virus infection in kidney transplant recipients using direct‐acting antiviral therapy: Qatar experience |
| title_full | Eradication of hepatitis C virus infection in kidney transplant recipients using direct‐acting antiviral therapy: Qatar experience |
| title_fullStr | Eradication of hepatitis C virus infection in kidney transplant recipients using direct‐acting antiviral therapy: Qatar experience |
| title_full_unstemmed | Eradication of hepatitis C virus infection in kidney transplant recipients using direct‐acting antiviral therapy: Qatar experience |
| title_short | Eradication of hepatitis C virus infection in kidney transplant recipients using direct‐acting antiviral therapy: Qatar experience |
| title_sort | Eradication of hepatitis C virus infection in kidney transplant recipients using direct‐acting antiviral therapy: Qatar experience |
| topic | Biomedical and clinical sciences Clinical sciences Immunology hepatitis C immunosuppression kidney function kidney transplantation |